Emergent Biosolutions (NYSE:EBS) Releases Quarterly Earnings Results, Beats Estimates By $0.03 EPS

Emergent Biosolutions (NYSE:EBS) posted its quarterly earnings results on Monday. The biopharmaceutical company reported ($0.36) EPS for the quarter, beating the consensus estimate of ($0.39) by $0.03, FiscalAI reports. Emergent Biosolutions had a negative net margin of 22.95% and a positive return on equity of 16.35%. The business had revenue of $110.00 million for the quarter, compared to analysts’ expectations of $123.22 million.

Here are the key takeaways from Emergent Biosolutions’ conference call:

• Full-year 2026 revenue guidance was reduced to $600 million–$645 million, reflecting lower expected MCM revenue as some U.S. government and international deliveries may shift into early 2027; commercial revenue is tracking toward the low end of the expected 20%–25% decline versus 2025.
• The company generated $122 million in year-to-date operating cash flow, ended the quarter with $226 million in liquidity, and reduced gross debt to $514 million after repurchasing $75 million of bond principal.
• Emergent expects restructuring actions to deliver approximately $40 million in annualized savings, with initial benefits beginning in the fourth quarter, and raised adjusted gross-margin guidance to 45%–47% due to operational improvements, product mix, and more stable NARCAN pricing.
• Third-quarter revenue fell to $110 million from $231 million a year earlier, while adjusted EBITDA was negative $5 million, pressured by MCM delivery timing, product mix, and competitive pricing and volume pressure in the naloxone market.
• Emergent said NARCAN remains the U.S. market leader despite new competitors, while international MCM activity reached 13 countries and contributed 22% of year-to-date MCM revenue; the company is also advancing pan-Ebola, pan-flu, AI-enabled development, and other growth programs.

Emergent Biosolutions Stock Performance

Shares of NYSE EBS opened at $6.42 on Tuesday. The business’s 50-day simple moving average is $6.50 and its 200-day simple moving average is $8.02. The company has a debt-to-equity ratio of 1.70, a quick ratio of 2.95 and a current ratio of 5.42. Emergent Biosolutions has a 52 week low of $4.36 and a 52 week high of $14.06. The firm has a market cap of $329.38 million, a price-to-earnings ratio of -1.81 and a beta of 2.37.

Insiders Place Their Bets

In other Emergent Biosolutions news, Director Donald Degolyer sold 17,800 shares of the company’s stock in a transaction that occurred on Wednesday, October 7th. The stock was sold at an average price of $7.09, for a total transaction of $126,202.00. Following the completion of the sale, the director owned 111,921 shares of the company’s stock, valued at $793,519.89. This represents a 13.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 6.00% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on EBS. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of Emergent Biosolutions in a research report on Wednesday, September 9th. JPMorgan Chase & Co. assumed coverage on shares of Emergent Biosolutions in a research report on Friday, August 21st. They set an “underweight” rating on the stock. Zacks Research raised shares of Emergent Biosolutions to a “hold” rating in a research report on Tuesday, August 11th. Finally, Weiss Ratings upgraded shares of Emergent Biosolutions from a “sell (d-)” rating to a “sell (d)” rating in a research note on Friday, August 21st. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $10.00.

Emergent Biosolutions News Summary

Here are the key news stories impacting Emergent Biosolutions this week:

• Positive Sentiment: Emergent reported third-quarter adjusted EPS of -$0.36, modestly better than the analyst estimate of -$0.39. Revenue of $110 million was in line with the company’s guidance and was supported by its biodefense, medical-countermeasures and naloxone businesses. Emergent Biosolutions Reports Third Quarter 2026 Financial Results
• Positive Sentiment: The restructuring program is expected to produce approximately $40 million in annualized savings, potentially improving margins and cash flow as Emergent advances its multi-year transformation. Emergent BioSolutions: 3 Key Takeaways for Long-Term Investors
• Neutral Sentiment: Management maintained that its diversified biodefense and medical-countermeasures portfolio provides a foundation for the company’s transformation, but investors will likely focus on whether the portfolio can deliver more consistent growth. Emergent BioSolutions Q3 2026 Earnings Call Transcript
• Negative Sentiment: Emergent lowered full-year revenue guidance to $600 million-$645 million and also reduced EBITDA guidance. The second straight outlook cut overshadows the small EPS beat and signals continued pressure on demand, execution or product timing. Emergent Biosolutions Guidance Update
• Negative Sentiment: Quarterly revenue of $110 million was below the $123.22 million analyst consensus, reinforcing concerns about near-term top-line momentum despite the company’s cost-reduction plans. Emergent BioSolutions Q3 Earnings Results

About Emergent Biosolutions

Emergent BioSolutions Inc is a life sciences company that develops, manufactures and supplies medical countermeasures for public health threats. Its portfolio has included products for protection against anthrax and smallpox, as well as treatments and emergency medicines used in overdose response and other acute-care settings.

The company has also provided contract development and manufacturing services for pharmaceutical and biotechnology companies, supporting activities such as drug substance and product manufacturing, packaging and related commercialization services.